
UPDATED APRIL 2025

native GALAXIS FRONTIER: CLAIMS OVERVIEW

Galaxis Frontier is the only microbial solution for dairy cows built on an extensive foundation of de novo rumen sequencing and advanced biotechnologies like next-generation sequencing, transcriptomics, and flow cytometry. These methods allowed us to predsely characterize the microbial makeup of highperforming dairy cows. From this data, we identified four keystone rumen microbes, essential to a balanced rumen microbiome, and stabilized them to remain viable at room temperature. When cows are fed Galaxis Frontier, their rumen environment shifts to a more efficient and sustainable state, enhancing overall animal health and productivity.



Pichia kudriavzevii (DY21)

Synthesizes catalytic enzymes that degrade fiber

Clostridium beijerinckii (DY20) Produces volatile fatty acids (VFA) as a fermentation byproduct

Ruminococcus bovis (DY10)

Resistant starch degrader, acetate producer, keystone species first isolated by Native Microbials


Butyrivibrio fibrisolvens (DY19)

Biohydrogenates LCFA into the precursor to endogenously synthesized conjugated linoleic acid (CLA) in milk

ACADEMIC DATA

Native Microbials has spent over \$3 million studying Galaxis Frontier and completed 9 academic trials at the following facilities: University of Illinois (Dr. James Drackley), Michigan State University (Dr. Mike Vandehaar), Cornell University (Dr. Tom Overton), University of Florida (Dr. Jose Santos), South Dakota State University (2 studies, Dr. Johann Osorio, Dr. Elias Uddin), University of Wisconsin (Dr. Jimena Laporta), DairyExperts (2 studies, Dr. Alfonso Lago). This data package makes Galaxis Frontier one of the most well researched dairy solutions in the industry.

Below are composite results from the 5 academic trials that have been published/submitted. Links to the published papers can be found on our research page: https://www.galaxisfrontier.com/research



15

10

5

0

Expected MY I+bs Improvment

COMMERCIAL TRIALS

In addition to conducting 9 academic trials, we've validated product performance on over 60,000 commercial dairy cows. These cows were studied in 21 on-farm treatment vs. control trials, with 12 more trials ongoing. Commercial performance aligns with expectations set from academic research.

COMPOSITE COMMERCIAL MILK IMPROVEMENT (starting DIM 30-150) OVERLAID ON ACADEMIC-BASED EXPECTATIONS (starting DIM 30-150)

50

100

250

1

200

150

Days Feeding


GALAXIS FRONTIER'S IMPACT ON ANIMAL HEALTH

EVIDENCE FOR IMPROVED HEALTH/LIVABILITY

In commercial treatment vs control trials that followed cows throughout their lactation, cull rates in cows enrolled early in lactation for a minimum of 8 weeks was recorded (shown right - results from one Holstein dairy).


We performed a Random-Effects meta- analysis across 14 independent commercial trials and found an average 17% reduction in cull rates (p < 0.0001).






REDUCED EARLY CULL RATES (<60 DIM)

Results from an on-farm treatment/control trial of ~6,000 Holstein cows enrolled pre-partum (~21 DIM)



IMPROVED COLOSTRUM QUANTITY + QUALITY





REAL DAIRYMEN. REAL RESULTS.

To view all of our customer testimonials, visit www.galaxisfrontier.com/testimonials.

WISCONSIN

Laporta, Jimena et al.,

2024. Manuscript in prep.